KRAS amplifications has been reported in various malignancies, primarily in pancreatic [59, 79], colorectal [80, 81] and lung [58, 82] tumors, but also have been noted in gastric [83], ovarian [84] and endometrial [85] malignancies, but less frequently in prostate cancers [46]. Here, KRAS is linked to prostate cancer.